Liraglutide Reduces HbA1C, Body Weight in Type 1 Diabetes

Liraglutide was also found to significantly reduce daily bolus and basal insulin
Liraglutide was also found to significantly reduce daily bolus and basal insulin

This article is written live from the American Association of Clinical Endocrinologists (AACE) 2017 Annual Meeting in Austin, TX. MPR will be reporting news on the latest findings from leading experts in endocrinology. Check back for more news from AACE 2017.


According to results of a meta-analysis presented at the AACE 2017 Annual Meeting, “liraglutide as compared to placebo causes a significant decrease in bolus insulin, basal insulin and body weight as well as a moderate decrease in HbA1c, in patients with T1DM [type 1 diabetes mellitus] after 12 weeks of treatment with a relatively good safety profile.”

The study aimed at analyzing data obtained from randomized controlled trials (RCTs) to determine the safety and efficacy of glucagon like peptide-1 receptor agonists (GLP-1RA) in patients with T1DM. Outcomes of the study included changes in HbA1c, basal and bolus insulin, and body weight, as well as the occurrence of adverse events.

The study authors identified 3 RCTs (212 patients total) which compared liraglutide to placebo. Results of the meta-analysis found a 0.29% reduction in HbA1c in patients receiving liraglutide compared to placebo (95% CI:
–0.52, –0.06; P=0.01). Lead study author Raju Panta, MD, MEd, FACP, of the State University of New York at Buffalo, in Buffalo, NY, commented, “this is a small but a significant reduction in HbA1c.”

Liraglutide was also found to significantly reduce daily bolus and basal insulin as well. The study authors reported that, compared to placebo, liraglutide reduced daily bolus insulin by 4.39 units (95% CI: –6.28, –2.49; P<0.00001) and daily basal insulin by 2.55 units (95% CI: –4.87, –0.22; P=0.03). Additionally, after 12 weeks of treatment, patients receiving liraglutide had a 4.56 kg reduction in body weight compared to patients receiving placebo (95% CI –5.42, –3.7; P<0.00001).

The study authors also reported on adverse events associated with treatment with liraglutide. Results of the study found that the risk of nausea was significantly increased for patients receiving liraglutide (odds ratio: 6.55; CI: 2.32, 18.48; P=0.0004). On the other hand, liraglutide did not significantly increase the risk of vomiting (odds ratio: 1.67; 95% CI: 0.34, 8.13; P=0.63).

In this meta-analysis, the efficacy and safety of liraglutide was demonstrated in patients with T1DM. The study authors added, “it is very likely that post-prandial suppression of glucagon by GLP-1RA is a key factor in controlling hyperglycemia in T1DM.”

For continuous endocrine news coverage from the AACE 2017 Annual Meeting, check back to MPR's AACE page for the latest updates.